Study of PROSPECT IV (Prostamol: Perspectives of Combined Therapy) in Patients with Benign Prostatic Hyperplasia
September 2020
in “
Scientific periodicals of Ukraine
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study aimed to evaluate the efficacy and safety of a nine-year combination therapy using "Flosin – Prostamol Uno" in patients with benign prostatic hyperplasia (BPH). Out of 94 patients from the previous PROSPECT III study, 37 were followed up for 9 years. The study compared two groups: 33 patients received "Flosin – Prostamol Uno," and 4 received "doxazosin – finasteride." Results indicated that "Flosin – Prostamol Uno" was highly effective and well-tolerated, with a lower incidence of adverse events (5.75%) compared to the control group (27%). The level of acute urinary retention in the treatment group was 19%. The study concluded that patient adherence to the "Flosin – Prostamol Uno" therapy was high, and it effectively reduced the risk of acute urinary retention.
